TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15234049
Drug: Beta-irradiation (beta-RT)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-irradiation (beta-RT) with (90)Sr, delivered 2500 cGy to the sclera surface at a dose rate of 200-250 cGy/min
Study: 2902671
Drug: broxaterol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: broxaterol (0.5 mg)
Study: 2902671
Drug: procaterol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: procaterol (0.05 mg)
Study: 28393317
Drug: MS medication
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS medication video (attention control)
Study: 26224613
Drug: Betamethasone injections
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone injections
Study: 21402616
Drug: lesogaberan (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: lesogaberan (65 mg twice daily)
Study: 18504447
Drug: High-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol cocoa (HF, 902 mg flavanols)
Study: 18504447
Drug: Low-flavanol cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol cocoa (LF, 36 mg flavanols)
Study: 17038680
Drug: Primaquine 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 45 mg total dose (15 mg/day)
Study: 17038680
Drug: Primaquine 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 105 mg total dose (15 mg/day)
Study: 17038680
Drug: Primaquine 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 210 mg total dose (15 mg/day)
Study: 9363045
Drug: Low-dosage abecarnil
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage abecarnil (3.0-7.0 mg daily)
Study: 9363045
Drug: High-dosage abecarnil
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage abecarnil (7.5-17.5 mg daily)
Study: 1491390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no remittive agents)
Study: 4006379
Drug: Uniphyl (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl (two 400 mg tablets) under fasting conditions
Study: 31686742
Drug: Isosorbide Mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide Mononitrate (ISMN) 20 mg/day
Study: 27669731
Drug: Individual Managing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Managing Anger Program (I-MAP), a Cognitive behavioural therapy (CBT) and mindfulness-based anger management intervention
Study: 11940031
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Therapy (FET) - 30 min daily sessions for 3 weeks
Study: 11940031
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Therapy (FET) - LFG
Study: 8592993
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 mg
Study: 8592993
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg
Study: 8592993
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg
Study: 8592993
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600 mg
Study: 8592993
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 300 mg twice daily for 6.5 days
Study: 8592993
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of probenecid
Study: 2913960
Drug: Topical methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical methotrexate 0.1%
Study: 2913960
Drug: Topical methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical methotrexate 0.5%
Study: 2913960
Drug: Topical methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical methotrexate 1%
Study: 30742522
Drug: 25% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% urea cream
Study: 25002178
Drug: Bivalirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (bolus 0.75 mg/kg; infusion 1.75 mg/kg per hour)
Study: 25002178
Drug: Heparin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (70 U/kg)
Study: 18469248
Drug: Turmeric supplementation
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric supplementation (55 mg oxalate/d for 4 weeks)
Study: 18469248
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (55 mg oxalate/d for 4 weeks)
Study: 18469248
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (water only)
Study: 16531835
Drug: Medical Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Symptom Validity Test (MSVT) administered to IME patients
Study: 10437188
Drug: Compound Tong
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Tong Jiang Oral Liquid with Da Huang (TJ)
Study: 10437188
Drug: Qi Yin
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi Yin Oral Liquid (QY)
Study: 1441852
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus heparin (control)
Study: 26280588
Drug: Polyaxial implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyaxial implants
Study: 26280588
Drug: Monoaxial implant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoaxial implant, cement-augmented, without laminectomy in patients 60 years or older
Study: 24885354
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone before the first radiotherapy and three days placebo thereafter
Study: 24885354
Drug: Four days
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four days 8 mg dexamethasone
Study: 24885354
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo for four days
Study: 18343806
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (lopinavir/ritonavir + zidovudine + lamivudine)
Study: 12657404
Drug: Thiopental sodium
Normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental sodium 5 mg/kg (Group 1)
Study: 12657404
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg (Group 2)
Study: 12657404
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg/kg (Group 3)
Study: 11253341
Drug: Immediate mobilization
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate mobilization and ambulation, external compression therapy, early Low Molecular Weight Heparin (LMWH) administration, and late oral anticoagulation.
Study: 1286052
Drug: Needle stick
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle stick (no injection)
Study: 1286052
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with epinephrine (5 micrograms/ml)
Study: 3084954
Drug: Reproterol infusion
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol infusion (0.2‐2.0 micrograms/kg/min in Saline)
Study: 3084954
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalation (75 micrograms/kg in 2 ml Saline every two hours)
Study: 3084954
Drug: Reproterol infusion
Normalized name: reproterol
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol infusion (2.0 micrograms/kg/min)
Study: 30125462
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced tacrolimus (EVR/rTAC) and steroid elimination
Study: 30125462
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids
Study: 27797674
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with 66 mg of isoflavones (SPI)
Study: 26001289
Drug: Lenalidomide (LEN)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide (LEN) treatment
Study: 19194127
Drug: Conventional carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional carboplatin plus etoposide (CE) - carboplatin AUC 5 on day 1 IV and etoposide 140 mg/m IV on days 1-3, q28 days
Study: 19194127
Drug: Dose-intensified carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-intensified carboplatin plus etoposide plus lenograstim - carboplatin AUC 5 on day 1 IV and etoposide 190 mg/m days 1-3 IV with lenograstim 263 microg subcutaneously on days 4-13, q21 days
Study: 15012621
Drug: Spironolactone plus
Normalized name: Spironolactone Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone plus finasteride (100 mg/day + 5 mg/day)
Study: 15012621
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/day) alone
Study: 11879339
Drug: Monotherapy (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (400 mg CBZ per day)
Study: 11879339
Drug: Polytherapy (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytherapy (200 mg CBZ plus 300 mg VPA per day)
Study: 8334827
Drug: Indomethacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (1 mg kg‐1)
Study: 8334827
Drug: Metoprolol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1.5 mg kg‐1)
Study: 3595669
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, vindesine (3 mg/m2 i.v., max 5 mg) days 1 and 8, CCNU (150 mg/m2 p.o., max 200 mg) day 1
Study: 3595669
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, DTIC (250 mg/m2 i.v. max 400 mg) days 1-5, CCNU (150 mg/m2 p.o. max 200 mg) day 1
Study: 30232866
Drug: Thermosensitive moxibustion
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermosensitive moxibustion (TSM), applied to bilateral Taichong (LR 3) and Qiuxu (GB 40) once daily for 15 days.
Study: 30232866
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Estazolam tablets, 1 mg/d, once daily for 15 days).
Study: 27058964
Drug: Single HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single HA injection
Study: 27058964
Drug: Double HA
Normalized name: HOUTTUYNIA CORDATA FLOWERING TOP 11.6 g in 100 mL / PERILLA FRUTESCENS LEAF 11.6 g in 100 mL TOPICAL LIQUID [Dr.Double Ha ULTRA SOOTHING ESSENCE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double HA injection
Study: 7593728
Drug: Moclobemide and
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide and Fluoxetine
Study: 2344514
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination by a urologist or general practitioner
Study: 7026542
Drug: Phenelzine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (mean 81 mg/day)
Study: 7026542
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean 144 mg/day)
Study: 30215460
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral TAP block using 40 mL 0.25% bupivacaine
Study: 22823027
Drug: Continued protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)
Study: 12017948
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of fenticonazole nitrate intravaginal ovules
Study: 12017948
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of myconazole vaginal ovules
Study: 7776934
Drug: rhDNase (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase (2.5 mg once daily)
Study: 1983214
Drug: Topical oxatomide
Normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxatomide gel 5%
Study: 28093837
Drug: Single-dose simulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose simulation education with structured debriefing and verbal feedback
Study: 10365191
Drug: Interactional Treatment
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactional Treatment (IT)
Study: 7495248
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 14 vitamins and 12 minerals at two to three times the US RDA
Study: 1783363
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amiloride (2 x 2.5 mg) and long‐acting furosemide (2 x 10 mg)
Study: 1783363
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg) and furosemide (20 mg)
Study: 6813814
Drug: EPCC combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPCC combined with aspirin (300 mg bid) and dipyridamole (75 mg tid)
Study: 31993943
Drug: Twice-daily cyclosporine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily cyclosporine
Study: 11811547
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg of D‐alpha‐tocopheryl acetate daily)
Study: 11811547
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg of slow release ascorbate daily)
Study: 7775548
Drug: Combined perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perioperative infusion of nifedipine and metoprolol (NM)
Study: 27025986
Drug: Oxycodone ER
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ER (Xtampza ER)
Study: 18335118
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 20 ml of honey before and after radiation therapy
Study: 18335118
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with 20 ml of saline before and after radiation therapy
Study: 22383098
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral sildenafil
Study: 14698783
Drug: [(99m)Tc]DTPA-mannosyl-dextran (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(99m)Tc]DTPA-mannosyl-dextran (all doses)
Study: 10714909
Drug: 7-day-Estradiol patch
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day-Estradiol patch (50 microg estradiol per day)
Study: 9187443
Drug: Involved-field radiotherapy
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field radiotherapy (IF-RT) given to 90% of patients in partial remission (PR) after chemotherapy.
Study: 9187443
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment for patients in complete remission (CR) after chemotherapy.
Study: 3516622
Drug: Fructose (0.325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (0.325 g/kg)
Study: 3516622
Drug: Glucose (0.325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (0.325 g/kg)
Study: 31023318
Drug: Perioperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative systemic therapy and CRS‐HIPEC
Study: 27310943
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for BDII for 12 weeks
Study: 22033719
Drug: Iterative Reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iterative Reconstruction (IR) at 275 mAs (15% dose reduction)
Study: 22033719
Drug: Iterative Reconstruction
Normalized name: CONSTRICTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iterative Reconstruction (IR) at 225 mAs (30% dose reduction)
Study: 22033719
Drug: Filtered Back-Projection
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filtered Back-Projection (FBP) at 320 mAs (standard dose)
Study: 22033719
Drug: Filtered Back-Projection
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filtered Back-Projection (FBP) at 275 mAs (15% dose reduction)
Study: 22033719
Drug: Filtered Back-Projection
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filtered Back-Projection (FBP) at 225 mAs (30% dose reduction)
Study: 20148254
Drug: 25‐G Quincke
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐G Quincke type spinal needle
Study: 20148254
Drug: 29‐G Quincke
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29‐G Quincke type spinal needle
Study: 19338490
Drug: C2 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 levels in schistosomal group (511 ‐/+ 118 nmol/L)
Study: 19338490
Drug: C2.5 levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2.5 levels in schistosomal group (730 ‐/+ 215 nmol/L)
Study: 2185452
Drug: Cefadroxil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (1 gm, single-dose)
Study: 2185452
Drug: Erythromycin (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (high-dose, 1-day regimen)
Study: 2185452
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no peritreatment antibiotics)
Study: 381887
Drug: Daunorubicin 60
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin 60 mg/M2 daily X 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia achieved
Study: 381887
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of daunorubicin 100 mg/M2 on day 1, cytosine arabinoside plus thioguanine 100 mg/M2 every 12 hours for five days
Study: 381887
Drug: 6-mercaptopurine 100
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine 100 mg/M2 daily
Study: 381887
Drug: 6-thioguanine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine 100 mg/M2 daily
Study: 381887
Drug: 50 mg/M2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/M2 of both 6-mercaptopurine and 6-thioguanine daily
Study: 31878810
Drug: hEGH gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: hEGH gel (Regen-D 150)
Study: 24227660
Drug: Canagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50 mg
Study: 19357528
Drug: Lamotrigine (236+/‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (236+/‐150 mg/day)
Study: 17855483
Drug: BQ-788 (ETB
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-788 (ETB receptor blockade)
Study: 17855483
Drug: BQ-788 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-788 and BQ-123 (combined ET receptor blockade)
Study: 17855483
Drug: BQ-123 (ETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (ETA receptor blockade)
Study: 9583767
Drug: Placebo analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo analgesia after buprenorphine treatment
Study: 9583767
Drug: Placebo respiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo respiratory depression after buprenorphine treatment
Study: 7662835
Drug: Antianginal drug
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal drug
Study: 2128879
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections or pulsatile subcutaneous administration of human menopausal gonadotropin (hMG)
Study: 2128879
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate and hMG
Study: 2128879
Drug: Various clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various clinical conditions and types of preparations administered
Study: 533574
Drug: Oral antipyrine
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipyrine treatment over 4 or 5 weeks in vegetarian Asians and non-vegetarians
Study: 533574
Drug: Oral antipyrine
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipyrine treatment
Study: 30148161
Drug: Polyherbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal formulation (PHF) 750 mg/d in three doses for 90 days
Study: 24106334
Drug: Clonidine 50
Normalized name: cloNIDine 500 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 50 µg
Study: 16265778
Drug: 3-IP (omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-IP (omega-3 fatty acid, 3 g/day)